Analysis of the initial efficacy of nedaplatin combined with megestrol in concurrent chemoradiotherapy for advanced cervical cancer.
- Author:
Qing-Hua KE
1
;
Shi-Qiong ZHOU
;
Xiao-Yan SU
;
Zhen LIU
;
Wen-Tao ZHANG
;
Ji-Yuan YANG
Author Information
- Publication Type:Journal Article
- MeSH: Adenocarcinoma; drug therapy; pathology; radiotherapy; Adult; Alopecia; chemically induced; Anemia; chemically induced; Antineoplastic Combined Chemotherapy Protocols; adverse effects; therapeutic use; Brachytherapy; Chemoradiotherapy; adverse effects; Diarrhea; chemically induced; Female; Follow-Up Studies; Humans; Iridium Radioisotopes; therapeutic use; Leukopenia; chemically induced; Megestrol; administration & dosage; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; administration & dosage; Particle Accelerators; Radiotherapy, High-Energy; Remission Induction; Survival Rate; Thrombocytopenia; chemically induced; Uterine Cervical Neoplasms; drug therapy; pathology; radiotherapy
- From: Chinese Journal of Oncology 2011;33(8):629-631
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the early efficacy of nedaplatin combined with megestrol in concurrent chemoradiotherapy for advanced cervical cancer.
METHODSForty-two cases of cervical cancer (FIGO IIb to IVa) were divided randomly into two groups: radiotherapy alone (21 cases) and radiation plus chemotherapy (Nedaplatin) group. The same radiotherapy was given to the two groups. Patients of the RT + C group received nedaplatin 30 mg/m2 in intravenous drip infusion once weekly on day 1, for 4 to 5 weeks, and megestrol 160 mg orally every day during the radiation therapy.
RESULTSThe early outcome: the complete remission rate was 81.0% and partial remission rate was 19.0% in the RT + C group, significantly better than the CR (38.1%) and PR (42.9%) in the RT group. The 1-year survival rates in the two groups were 100% (21/21) and 81.0% (17/21), respectively, with a significant difference between the two groups (P<0.05).
CONCLUSIONSThe combination of nedaplatin and megestrol with concurrent chemoradiotherapy can improve the early outcome of advanced cervical cancer, with somewhat increased but tolerable adverse effects.
